BioSpace News Archive

Bicycle Therapeutics plc today announced that management will participate in the following investor conferences in November.

Volastra Therapeutics , a discovery and clinical-stage cancer biotechnology company, today announced the dosing of the first patient in a Phase I/II clinical trial evaluating VLS-1488.

VYNE Therapeutics Inc. today announced new preclinical data showing the positive effect of its oral small molecule BD2-selective BET inhibitor, VYN202, in preclinical models of psoriasis and rheumatoid arthritis.

Alterity Therapeutics Limited, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2023.

Hexiris Pharma Inc. is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee.

Applied UV Inc. (NASDAQ: AUVI), a pioneer in UV disinfection technology, is elated to announce today that the United States Patent and Trademark Office (USPTO) issued a patent US 2023/0059472 A1 for the Company’s Airo™ Vortex, encompassing advanced disinfection capabilities and Photocatalytic Oxidation (PCO).

Reviva Pharmaceuticals Holdings, Inc. today announced positive topline results and successful completion of its pivotal Phase 3 RECOVER trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin-dopamine signaling modulator in adults with schizophrenia.

Dyne Therapeutics, Inc. today reported financial results for the third quarter of 2023 and provided an update on progress and upcoming milestones for its Phase 1/2 ACHIEVE and DELIVER clinical trials.

ImmPACT Bio USA , Inc. today announced that it will participate in the 2023 Truist Securities BioPharma Symposium, to be held from November 8-9, 2023.

Cabaletta Bio, Inc. announced that the Company will participate in three upcoming investor conferences in November.